Genus PLC
LSE:GNS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Genus PLC
Genus PLC
Total Current Assets
Genus PLC
Total Current Assets Peer Comparison
CNTA
EXAI
AUTL
BCYC
IMCR
Competitive Total Current Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Genus PLC
LSE:GNS
|
Total Current Assets
£277.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Current Assets
$315.1m
|
CAGR 3-Years
204%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Total Current Assets
£404.9m
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Total Current Assets
$275.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Current Assets
$516m
|
CAGR 3-Years
34%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Current Assets
£528.8m
|
CAGR 3-Years
51%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
See Also
What is Genus PLC's Total Current Assets?
Total Current Assets
277.4m
GBP
Based on the financial report for Dec 31, 2023, Genus PLC's Total Current Assets amounts to 277.4m GBP.
What is Genus PLC's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
5%
Over the last year, the Total Current Assets growth was 2%. The average annual Total Current Assets growth rates for Genus PLC have been 7% over the past three years , 8% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
